Great Entrepreneurs is pleased to announce The Top 50 BioTech Entrepreneurs of 2024. The biotechnology sector stands at the intersection of science, technology, and medicine, driving remarkable advancements in the way we understand and treat diseases. This year’s awardees hail from a range of disciplines, including genetic engineering, synthetic biology, and immunotherapy, to name a few. By combining scientific expertise with entrepreneurial spirit, these leaders are revolutionizing the development of treatments for conditions that have long eluded effective intervention.
These leaders not only push the boundaries of scientific research but also navigate the complexities of bringing their innovations to market, ensuring that breakthroughs translate into accessible healthcare solutions. By fostering collaboration across academia, industry, and clinical practice, they create synergies that accelerate discovery and development processes, ultimately revolutionizing patient care and inspiring a healthier future worldwide.
Among this year’s awardees, Emily Leproust, Co-Founder and CEO of Twist Bioscience, has emerged as a leader in synthetic biology, pioneering a high-throughput DNA synthesis platform that enhances gene synthesis processes across various applications. Nello Mainolfi, Founder and CEO of Kymera Therapeutics, has made significant strides in the field of targeted protein degradation, establishing a robust pipeline of first-in-class therapies that promise to address critical health issues. Additionally, Rachel Haurwitz, Co-Founder and CEO of Caribou Biosciences, is leading the development of transformative therapies for patients with devastating diseases through her innovative genome-editing platform.
This year’s awardees were selected through a methodical process and careful consideration of each candidate’s career track record and industry contributions. Please join us in celebrating The Top 50 BioTech Entrepreneurs of 2024.
1. Tim Van Hauwermeiren
Co-Founder, Chief Executive Officer, argenx
Tim Van Hauwermeiren is the Co-Founded and Chief Executive Officer of argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. He has served as CEO since 2008 and has been a member of the Board of Directors since 2014. Under his leadership, argenx collaborates with academic researchers through its Immunology Innovation Program to develop antibody-based medicines.
Van Hauwermeiren has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors, including at Ablynx and Procter and Gamble. He holds both a bachelor’s and master’s degree in bioengineering from Ghent University and an MBA from The Vlerick School of Management. Additionally, he serves on the Board of Directors of iTeos Pharmaceuticals and Aelin Therapeutics where he is Chairman.
2. Martine Rothblatt
Founder, Chairperson, and Chief Executive Officer, United Therapeutics
Dr. Martine Rothblatt founded United Therapeutics in 1996 and has served as Chairperson and Chief Executive Officer since its inception. United Therapeutics is a biotechnology company focused on creating unique products to address the medical needs of patients with chronic illnesses. Under her leadership, the company emphasizes innovation and a commitment to its stakeholders.
Previously, Dr. Rothblatt founded satellite radio company SiriusXM. She holds nine U.S. patents as an inventor or co-inventor, with additional applications pending. Her book, Your Life or Mine: How Geoethics Can Resolve the Conflict Between Private and Public Interests in Xenotransplantation, anticipated the need both for global virus bio-surveillance and a greatly expanded supply of transplantable organs. Dr. Rothblatt graduated from University of California, Los Angeles with a JD and an MBA.
3. Emily Leproust
Co-Founder and CEO, Twist Bioscience
Emily Leproust is the Co-Founder and Chief Executive Officer of Twist Bioscience, a synthetic biology and genomics company that has developed a DNA synthesis platform for industrial applications. As a pioneer in high-throughput DNA synthesis and sequencing, Dr. Leproust is enhancing gene synthesis processes to support the growth of synthetic biology applications across various fields, including medicine, DNA data storage, agricultural biology, and industrial chemicals.
Previously Leproust held several positions at Agilent Technologies, where she successfully architected the SureSelect product line that lowered the cost of sequencing and elucidated mechanisms responsible for dozens of Mendelian diseases. She also developed the Oligo Library Synthesis technology, where she initiated and led product and business development activities for the team.
Dr. Leproust has published over 30 peer-reviewed papers and is the author of numerous patents. She holds a PhD in organic chemistry and nucleic acids chemistry from the University of Houston and a master’s degree in industrial chemistry from CPE Lyon.
4. Jan Møller Mikkelsen
Founder, CEO and President, Ascendis Pharma
Jan Møller Mikkelsen founded Ascendis Pharma and has served as President, Chief Executive Officer, and Board member since its inception. The company utilizes its innovative TransCon technology platform to develop a fully integrated biopharma company focused on improving patients’ lives.
Previously, Mikkelsen was President and Chief Executive Officer of LifeCycle Pharma A/S, now Veloxis Pharmaceuticals A/S. Prior to that, he was President of the Pharmaceutical Division of Maxygen, Inc. Earlier in his career Mikkelsen held various positions at Novo Nordisk A/S, including Vice President of Protein Discovery. Mikkelsen received a PhD-equivalent degree in biochemistry from the University of Odense, Denmark and pursued his post-doctoral research at Children’s Hospital Oakland in California.
5. Stephen Turner
Co-Founder and Chief Technical Officer, PacBio
Stephen Turner is the Co-Founder and Chief Technical Officer of PacBio. Turner founded PacBio, formerly Nanofluidics, and in 2004 secured its Series A funding. PacBio is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems.
Turner earned a PhD in physics from Cornell University, where he collaborated with Prof. Harold Craighead to study biomolecules in nano-fabricated structures. He was part of the project team that developed the technology currently used by PacBio and co-authored the cover story in Science magazine, which introduced this technology to the scientific community. He holds bachelor’s degrees in applied mathematics, electrical engineering, and physics from the University of Wisconsin, Madison.
6. Neil Kumar
Co-Founder and CEO, BridgeBio
Neil Kumar is a Co-Founder of BridgeBio Pharma, where he has served as Chief Executive Officer and a Board member since April 2015. BridgeBio is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. Dr. Kumar has also served as the Chief Executive Officer Eidos Therapeutics, Inc., a clinical-stage subsidiary, and as a board member since 2016.
Previously, Kumar served as Interim VP of Business Development at MyoKardia, Inc., a clinical-stage biopharmaceutical company. Prior to that, Dr. Kumar served as a Principal at Third Rock Ventures. Before joining Third Rock Ventures, he served as an Associate Principal at McKinsey and Company. Kumar holds both bachelor’s and master’s degrees in chemical engineering from Stanford University and a PhD in chemical engineering from the Massachusetts Institute of Technology.
7. Juan Jaen
President, Co-Founder, and Board of Directors, Arcus Biosciences
Juan Jaen is the President and Co-Founder of Arcus Biosciences, where he also serves on the Board of Directors. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer treatment.
The company collaborates with industry partners, patients, and physicians worldwide to advance first- or best-in-class medicines targeting well-characterized biological pathways, as well as exploring innovative, biology-driven combinations. Dr. Jaen has over 30 years of experience in drug discovery and development, co-founding Arcus in 2015.
Before starting Arcus, Dr. Jaen was Co-Founder and President of Flexus Biosciences. He was also Chief Scientific Officer and SVP of Drug Discovery at ChemoCentryx, where he led the discovery and progression into the clinic of eight novel immunology drug candidates. Dr. Jaen has also held various positions at Amgen, Tularik, and Parke-Davis/Warner-Lambert.
Dr. Jaen is an inventor on 50 patents and has helped the advancement of over 20 novel molecules into clinical development across a range of indications. He graduated from the University of Michigan with a PhD in chemistry and from the Universidad Complutense de Madrid with a masters’ degree in chemistry.
8. Chris Gibson
Co-Founder and CEO, Recursion Pharmaceuticals
Chris Gibson is the Co-Founder and CEO of Recursion, a clinical-stage technology company focused on advancing drug discovery through biological insights. The company's mission is supported by the Recursion OS, a platform that integrates various technologies to continuously expand one of the world's largest proprietary biological and chemical datasets. Recursion employs machine-learning algorithms to identify trillions of searchable relationships within its dataset, enhancing the drug discovery process.
Gibson developed the technology and approach that seeded Recursion as part of his MD/PhD work in the lab of Co-Founder Dr. Dean Li, current President of Merck Research Labs, while at the University of Utah. After completing his PhD, he left medical school to focus on building Recursion into a rapidly growing company. Gibson holds degrees in bioengineering and management from Rice University.
9. James Sabry
Co-Founder, Member, Scientific Advisory Board, Cytokinetics
James Sabry is the Co-Founder and Member of Cytokinetics, a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. Sabry also currently sits on the company’s scientific advisory board.
Prior to Cytokinetics, Sabry held faculty positions at the University of California, San Francisco and Harvard Medical School. He served on the Board of Directors of HopeLab, a not-for-profit organization developing innovative technologies for the management of cancer, obesity, and other diseases.
Sabry is a former member of the Dean's Council of the Kennedy School of Government at Harvard University and served on the advisory board of the California Institute of Quantitative Biosciences. He holds an MD from Queen’s University and a PhD in neuroscience from the University of California, San Francisco.
10. Jurgi Camblong
Co-Founder and CEO, SOPHiA GENETICS
Jurgi Camblong is the Co-Founder and Chief Executive Officer of SOPHiA GENETICS, a cloud-native healthcare technology company focused on expanding access to data-driven medicine. The company leverages AI to enhance patient care for cancer and rare disorders globally. It developed the SOPHiA DDM Platform, which analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions.
Dr. Camblong holds a PhD in life sciences from the University of Geneva and an Executive MBA in management of technology from EPFL/HEC Lausanne. He is a published molecular biologist, with work featured in Cell, Science, and Nature. In 2011, he co-founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz and has served on the Board of Directors since March 2011.
11. Craig Crews
Founder, Arvinas
Craig Crews is the Founder of Arvinas, a clinical-stage biotechnology company focused on developing therapies that degrade disease-causing proteins to improve the lives of patients with debilitating and life-threatening diseases. He has worked extensively with pharmaceutical companies to support their research and development pipelines with novel drug discovery ideas. His previous venture, Proteolix, founded in 2003, developed Kyprolis, a drug approved by the FDA for treating multiple myeloma, and was sold in 2009 for $851 million.
Dr. Crews is the Lewis B. Cullman Professor of molecular, cellular and developmental biology and professor of chemistry and pharmacology at Yale University. Central to Arvinas’ proprietary approach is the targeting of disease-causing proteins for degradation, resulting in their elimination from the body. Arvinas worked with the Yale Office of Cooperative Research to secure intellectual property protection. Crews graduated from Harvard University with a PhD in biochemistry and from the University of Virginia with an undergraduate degree in chemistry.
12. David Walt
Founder and Director, Quanterix
David R. Walt is the Scientific Founder of Quanterix, a company that develops ultra-sensitive biomarker detection technologies. Quanterix utilizes its proprietary Simoa (Single Molecule Array) platform to measure low-abundance biomarkers in blood and other biological samples, enabling researchers to detect and monitor various diseases, including neurological disorders and cancer.
Previously, Dr. Walt was University Professor at Tufts University. He has co-founded several other life sciences companies including Illumina Inc., Ultivue, Inc., Arbor Biotechnologies, Sherlock Biosciences and Vizgen. He also serves on the board of Exicure, Inc. Dr. Walt received a bachelor’s degree in chemistry from the University of Michigan, a PhD in chemical biology from SUNY at Stony Brook, and did postdoctoral studies at MIT.
13. Riley Ennis
Co-Founder and Chief Product Officer, Freenome
Riley Ennis is the Co-Founder and Chief Product Officer at Freenome, where he leads the clinical and commercial development of the company's noninvasive blood tests for early cancer detection. Freenome utilizes a multiomics approach that combines advanced computational biology and machine learning to identify cancer at its earliest and most treatable stages. The company aims to make cancer screening more accessible, starting with its focus on colorectal cancer through innovative blood tests.
A Thiel Fellow, Ennis developed a cancer vaccine and founded his first biotech company, Immudicon, while still in high school. He has co-authored several publications and worked as a visiting scientist with Novartis. Ennis has also worked as an analyst at Morgan Stanley and an associate at Bridgewater. His previous biotech experience includes work at Foundation Medicine, Syros Pharmaceuticals, Adimab, and Emergent Biosolutions. Ennis graduated from Dartmouth College with an undergraduate degree in molecular biology.
14. Samuel Waksal
Founder and Founding Chairman, MeiraGTx
Dr. Samuel Waksal is the Founder and Founding Chairman of MeiraGTx, a company based in London and New York that focuses on gene regulation, ocular gene therapy, xerostomia, and neurodegeneration. He was also a founding director of Medicis Pharmaceuticals, a dermatology company acquired by Valeant.
Dr. Waksal also founded Kadmon Holdings, a publicly traded biopharmaceutical company dedicated to developing medicines in oncology, infectious diseases, immunology, and metabolic diseases, where he served as Chairman and Chief Executive Officer. Additionally, he established Merlin, a key part of Somatix, recognized as one of the early gene therapy companies.
Previously, Dr. Waksal was a professor of pathology and director of the Division of Immunotherapy at the Mount Sinai School of Medicine in New York. His research experience includes roles as a visiting investigator at the National Cancer Institute, a research associate at Stanford University Medical School, an assistant professor at Tufts University School of Medicine, and a senior scientist at the Tufts Cancer Research Center.
Dr. Waksal has been a scholar of the Leukemia Society of America and has served as a visiting professor at the Pasteur Institute in France and the Weizmann Institute of Science in Israel. He earned his doctorate in immunology from The Ohio State University College of Medicine.
15. Michael Weiss
Founder, Chairman, President, and Chief Executive Officer, TG Therapeutics
Michael S. Weiss founded and has served as the Chairman, President, and Chief Executive Officer of TG Therapeutics since 2011. TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
Weiss previously founded ACCESS Oncology, where he served as CEO until its merger with Keryx Biopharmaceuticals, after which he continued as Chairman and CEO until mid-2009. There, he was instrumental in acquiring and developing AURYXIA, which is approved for treating patients on dialysis.
Prior to founding ACCESS Oncology, Weiss worked as a lawyer and later as an investor in biotech venture capital. He remains passionate about supporting early-stage biotech companies and currently serves as Vice Chairman of Fortress Biotech and Chairman of Checkpoint Therapeutics and Mustang Bio. He began his career as a lawyer at Cravath, Swaine & Moore.
16. Grant Pickering
Co-Founder, CEO, Director, Vaxcyte
Grant Pickering is the Co-Founder, Chief Executive Officer, and Director of Vaxcyte, a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Pickering is a seasoned pharmaceutical and biotech executive with over 30 years of experience across vaccines and immunotherapeutic drug development and commercialization, as well as the successful formation and financing of multiple platform companies.
Prior to founding Vaxcyte, Pickering served as the CEO of Mymetics Corporation, a European-based vaccine company developing a prophylactic RSV vaccine based on a virosomal platform technology. Previously, he was an executive-in-residence at Kleiner, Perkins, Caufield and Byers, while also serving as the CEO at Juvaris BioTherapeutics.
Under his leadership, Juvaris’ immunotherapeutic and vaccine adjuvant platform yielded multiple animal health products, launched by its alliance partner Bayer HealthCare, including Zelnate and Victrio.
Pickering began his career at Glaxo and Johnson & Johnson in sales, marketing, and clinical research roles. He currently serves on the board of directors of Athira Pharma, Inc. He earned a bachelor’s degree in marketing from Pennsylvania State University and an MBA from Georgetown University.
17. Ken Mills
Co-Founder and Chairman of the Board of Directors, REGENXBIO
Ken Mills is the Chairman of the Board of Directors at REGENXBIO, having previously served as the founding President and Chief Executive Officer from 2009 to 2024. He led the company's initial public offering in 2015 and played a crucial role in developing REGENXBIO into a leading gene therapy biotech with comprehensive capabilities in research and development, clinical trials, and manufacturing. Under his leadership, the company advanced its proprietary NAV Technology Platform, significantly impacting the field of AAV gene therapy.
Prior to REGENXBIO, Mills served as Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, where he was a part of the founding management team and worked to establish the company operations and ongoing business strategy. In this position, Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities.
Prior to that, Mills was Director of Business Development for IGEN International, a medical diagnostics company. Mills holds a bachelor’s degree in chemistry from the Massachusetts Institute of Technology.
18. Steve Harr
Co-Founder, President and Chief Executive Officer, Sana Biotechnology
Steve Harr is the President and Chief Executive Officer of Sana Biotechnology, a company focused on creating and delivering engineered cells as therapies for patients, with a vision of repairing and controlling genes and replacing missing or damaged cells. Sana aims to make these advanced therapies accessible to patients, leveraging its expertise in gene and cell therapy to develop innovative solutions for a variety of diseases.
Prior to co-founding Sana, Harr served as Chief Financial Officer and Head of Corporate Development for Juno Therapeutics until its acquisition by Celgene. He was also a member of the Board of Directors of Loxo Oncology prior to its acquisition by Eli Lilly. Additionally, Harr co-founded JW Therapeutics, a cell therapy company based in China.
Before joining Juno, Harr held positions at Morgan Stanley, where he was Managing Director and Head of Biotechnology Investment Banking, as well as a biotech research analyst and co-head of global healthcare research. Harr holds a bachelor’s degree in economics from College of the Holy Cross and an MD from Johns Hopkins University School of Medicine.
19. Greg Verdine
Co-Founder, Wave Life Sciences
Gregory L. Verdine is a Co-Founder of Wave Life Sciences and has served on its Board of Directors since 2013. Wave Life Sciences is a biotechnology company dedicated to harnessing the potential of RNA medicines to improve human health. The company's PRISM platform integrates multiple modalities, innovative chemistry, and insights from human genetics to advance treatments for both rare and common disorders.
Since 1989, Dr. Verdine has been the Erving Professor of Chemistry at Harvard University and Harvard Medical School, where he is now Emeritus. He co-founded the Gloucester Marine Genomics Institute and the Gloucester Biotechnology Academy, serving as the Founding President.
Dr. Verdine is also a Co-Founder of Fog Pharmaceuticals Inc., currently serving as Vice Chairman of the board of directors. He also holds the positions of President and CEO at LifeMine Therapeutics Inc. Previously, he founded Warp Drive Bio, where he served as Chief Scientific Officer and CEO, and was a Founder of Enanta Pharmaceuticals, serving on its board until its initial public offering.
20. Troy Wilson
Co-Founder and Executive Chairman Of The Board Of Directors, Avidity Biosciences
Troy Wilson is the Co-Founder and Chairman of the Board at Avidity Biosciences, a biotechnology company focused on revolutionizing the delivery of RNA therapeutics through its innovative Antibody Oligonucleotide Conjugates (AOCs). Avidity's mission is to improve lives by targeting the underlying genetic drivers of diseases, enabling treatments for both rare and common conditions.
Dr. Wilson currently also serves as President and Chief Executive Officer and Chairman of Kura Oncology. Previously, he co-founded and served as President and CEO of Araxes Pharma LLC and Wellspring Biosciences, where he and his team pioneered the discovery and development of small molecule inhibitors of the KRAS oncoprotein.
Earlier in his career, Dr. Wilson co-founded and served as President and CEO of Intellikine, a private biopharmaceutical company, acquired by Takeda Pharmaceuticals. He also co-founded and served as Chief Business Officer of Ambrx, acquired by Johnson & Johnson Innovative Medicines. Dr. Wilson holds a JD from New York University as well as a PhD in bioorganic chemistry and bachelor’s degree in biophysics from the University of California, Berkeley.
21. Daphne Koller
Founder and CEO, Board Member, insitro
Daphne Koller is the Founder and Chief Executive Officer of Insitro, a biotechnology company that leverages machine learning and high-throughput biology to enhance drug discovery and development processes. Insitro aims to transform the traditional methods of discovering and developing therapeutics by integrating large datasets and advanced computational techniques to model diseases and identify new therapeutic targets.
Previously, Koller was the Co-Founder, Co-CEO, and President of online education platform Coursera. She is also the Co-Founder of Engageli, an interactive digital learning platform aimed at improving learning outcomes. Koller was the Rajeev Motwani Professor of Computer Science at Stanford University for 18 years and continues as an adjunct faculty member.
Additionally, Koller held the position of Chief Computing Officer at Calico, an Alphabet company focused on healthcare. Koller graduated from Stanford University with a PhD in computer science and from The Hebrew University of Jerusalem with a master’s degree in computer science and an undergraduate degree in mathematics and computer science.
22. Molly Gibson
Co-Founder and Chief Innovation Officer, Generate:Biomedicines
Molly Gibson is the Co-Founder and Chief Innovation Officer of Generate:Biomedicines, a Flagship Pioneering company. At Generate, Gibson oversees corporate strategy, platform and data strategy, and an innovation group called G:Labs that explores novel applications of The Generate Platform.
Gibson is also an origination partner at Flagship Pioneering. Through her role in Flagship Labs, she has contributed to the launch and growth of Tessera Therapeutics and Cobalt Biomedicines. Gibson’s work has resulted in multiple pending patents and publications, including articles in Science and Nature.
Gibson holds a PhD in computational and systems biology from Washington University. At Washington University, she collaborated with St. Louis Children's Hospital to study the effects of early life interventions on development of the preterm infant gut microbiome and health outcomes.
23. Arthur Weiss
Co-Founder and Member of Scientific Advisory Board, Nurix Therapeutics
Arthur Weiss is the Co-Founder and Member of Scientific Advisory Board of Nurix Therapeutics, a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecules and antibody therapies. The company focuses on modulating cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Dr. Weiss is a pioneer in cell biology and signal transduction.
Dr. Weiss is a Howard Hughes Medical Institute Investigator and Ephraim P. Engleman Distinguished Professor at the University of California, San Francisco. He has previously served as the President of the American Association of Immunologists. He was also elected to the American Academy of Arts and Sciences, the National Academy of Sciences, and the Institute of Medicine.
Dr. Weiss holds a bachelor’s degree from Johns Hopkins University and earned his MD and PhD from the University of Chicago School of Medicine. He did postdoctoral training at the Swiss Institute for Experimental Cancer Research and his clinical training in internal medicine and rheumatology at UCSF.
24. Sekar Kathiresan
Co-Founder, Chief Executive Officer, and Board Member, Verve Therapeutics
Dr. Sekar Kathiresan is the Co-Founder and Chief Executive Officer of Verve Therapeutics, a clinical-stage company focused on developing a new class of genetic medicines for cardiovascular disease. Verve aims to transform treatment approaches from chronic management to single-course gene editing therapies.
Dr. Kathiresan has dedicated his career to understanding the inherited factors contributing to heart attacks and leveraging these insights to enhance the care of cardiovascular disease. Based on his discoveries in human genetic mutations that confer resistance to cardiovascular disease, Sek co-founded Verve Therapeutics with a vision to create a pipeline of single-course, gene editing therapies aimed at addressing the root causes of this highly prevalent and life-threatening disease.
Prior to Verve, Kathiresan served in a variety of roles including director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine, director of the Cardiovascular Disease Initiative at the Broad Institute, and professor of medicine at Harvard Medical School. At Harvard, Kathiresan’s research laboratory focused on understanding the inherited basis for blood lipids and myocardial infarction.
Kathiresan holds a bachelor’s degree in history from the University of Pennsylvania and an MD from Harvard Medical School. He completed clinical training in internal medicine and cardiology at MGH and postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.
25. Arie Belldegrun
Co-Founder and Executive Chairman, Allogene Therapeutics
Arie Belldegrun is the Executive Chairman and Co-Founder of Allogene Therapeutics, a clinical stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell therapies for cancer. The company aims to create therapies that leverage genetically modified T cells from healthy donors, potentially offering more accessible and scalable treatment options compared to traditional autologous CAR T therapies, which use a patient's own T cells.
Previously, Belldegrun founded Kite Pharma, a biopharmaceutical company dedicated to developing innovative cancer immunotherapies. He served as Chairman, President, and CEO until Kite was acquired by Gilead Sciences. Throughout his career in life sciences, he has played a key role in founding and advancing several successful biopharmaceutical companies, including Cougar Biotechnology and Agensys.
Currently, Belldegrun serves as Chairman of Two River Group, UroGen Pharma, and Bellco Capital, and as co-Chairman of Breakthrough Properties. He is also a Co-Founder and Senior Managing Director of Vida Ventures, a life science venture group with offices in Boston and Los Angeles. Additionally, he holds the Roy and Carol Doumani Chair in Urologic Oncology and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA.
Prior to his tenure at UCLA, he was a research fellow at the National Cancer Institute/NIH under Dr. Steven A. Rosenberg. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School.
26. Bassil Dahiyat
Founder, President, Chief Executive Officer, and Director, Xencor
Bassil I. Dahiyat has served as Xencor’s Founder, President, and Chief Executive Officer since 2005 and as a member of the Board since 1997. Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb technology are in clinical development, and multiple XmAb medicines are marketed by partners. Dr. Dahiyat has more than 25 years of experience in the biotechnology business.
Previously, Dr. Dahiyat served as Xencor’s Chief Scientific Officer. He also currently serves on the board of directors of Kodiak Sciences Inc., a publicly traded biopharmaceutical company. Dr. Dahiyat holds a PhD in chemistry from the California Institute of Technology and both bachelor’s and master’s degrees in biomedical engineering from Johns Hopkins University.
27. Ken Drazan
Co-Founder, Chairman and CEO, ArsenalBio
Ken Drazan is Chairman, Chief Executive Officer, and Co-Founder of ArsenalBio. Arsenal Biosciences, Inc., headquartered in San Francisco, California, is a clinical stage programmable cell therapy company focusing on discovering and developing a pipeline of next-generation autologous T cell therapies to defeat cancer.
Immediately prior to Arsenal, Drazan held the positions of President and Chief Business Officer of GRAIL. Prior to GRAIL, Drazan founded and was a Board Director of Verb Surgical. Drazan also co-founded private equity firm Bertram Capital.
Drazan is a board-certified liver transplant surgeon with previous faculty appointments at Stanford and UCLA. Drazan graduated from the SUNY Downstate Medical Center School of Public Health with an MD and from Yale University with an undergraduate degree in economics.
28. J. Kelly Ganjei
Founder, President and Chief Executive Officer, AmplifyBio
Kelly Ganjei is the Founder, President and Chief Executive Officer of AmplifyBio, a biotechnology company developing cell and gene therapies. The company's mission is to create pathways for novel treatment advances, cutting-edge technologies, and new research frontiers to advance medical breakthroughs, treatments, and cures for disease.
Ganjei is a proven leader with 26 years of experience in the life science, venture capital and IT sectors. Most recently, Ganjei was the CEO for Cognate BioServices, a leading contract development and manufacturing organization (CDMO) in the cell therapy space and the leading CDMO in autologous cell therapies.
Ganjei has a strong track record of guiding companies through various stages of development, from start-up to rapid growth and into stable multinational operations. He is passionate about fostering quality and culture within organizations and building teams that prioritize patient care while enjoying their work. Ganjei holds a bachelor’s degree in microbiology from the University of Maryland.
29. Nello Mainolfi
Founder, President and CEO, Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer of Kymera Therapeutics. Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives.
Under Mainolfi’s leadership, Kymera has advanced a novel modality and built a pipeline of multiple clinical stage, first-in-class degrader programs across a variety of indications, developed a best-in-class drug discovery platform, raised more than $1 billion in capital, and formed strategic collaborations with major biopharmaceutical companies.
Mainolfi began his career at Novartis, leading cross-functional teams that identified several novel investigational medicines including the first-in-class, FDA approved, factor B inhibitor iptacopan. Before founding Kymera, Mainolfi was an Entrepreneur-in-Residence at Atlas Venture. He studied at Imperial College, University of London, and The Scripps Research Institute in California and has authored more than 100 publications and patents.
30. Steven Paul
Senior Advisor, Co-Founder, and Board Member, Voyager Therapeutics
Steven Paul is a Senior Advisor, Co-Founder, and Board Member of Voyager Therapeutics. Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS).
Dr. Paul brings to Voyager more than 35 years of neuroscience expertise and an extensive track record in CNS drug discovery and development. As a Venture Partner at Third Rock, he helps lead the ideation and development of new companies, including Voyager, where he has served as Interim President of R&D since the company’s formation in 2014.
Prior to Third Rock, Dr. Paul spent 17 years at Eli Lilly and Company in key leadership roles, including Executive Vice President for Science and Technology and President of the Lilly Research Laboratories, as well as former Vice President of Discovery Research and Neuroscience Research.
Before joining Voyager, Dr. Paul was the Founding Director of the Appel Alzheimer's Disease Research Institute, where he was the Principal Investigator of the Institute’s novel AAV gene therapy program for Alzheimer’s disease, as well as Professor of Neuroscience, Psychiatry and Pharmacology at Weill Cornell Medical College.
Dr. Paul holds a bachelor’s degree in biology and psychology from Tulane University and a master’s degree and MD from the Tulane University School of Medicine.
31. Michel Detheux
Co-Founder, President and CEO, ITeos Therapeutics
Michel Detheux is the Co-Founder, President, and Chief Executive Officer of ITeos Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new generation of immuno-oncology therapeutics. Dr. Detheux has held the role of CEO since the company’s inception in 2012.
During his tenure, Dr. Detheux has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, Dr. Detheux spearheaded the strategic collaboration with GlaxoSmithKline to co-develop and co-commercialize iTeos’ differentiated anti-TIGIT antibody for a total value of $2 billion.
Dr. Detheux previously served as a director at Ludwig Cancer Research and worked in various scientific and business development roles at Ogeda. He currently serves as Chairman of the Board at Egle Therapeutics. Dr. Detheux holds a degree in chemical engineering and a PhD in biochemistry from Université Catholique de Louvain.
32. Robert Hariri
Chairperson, Founder and CEO, Celularity
Dr. Robert Hariri is the Chairperson, Founder, and Chief Executive Officer of Celularity, Inc., a leading human cellular therapeutics company. Celularity is focused on developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies sourced from postpartum placentas.
Previously, Dr. Hariri was the Founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. He also co-founded Human Longevity, Inc., a genomic-based health intelligence company, and has held positions on various public boards, including Cryoport.
Dr. Hariri is recognized for pioneering the use of stem cells to treat life-threatening diseases and continues to advance innovations in immuno-oncology, cell therapeutics, tissue engineering, and functional regeneration. He completed his undergraduate training at Columbia University and earned his M.D. and Ph.D. from Cornell University.
Additionally, Dr. Hariri was a surgical resident and fellow in neurosurgery at The New York Hospital-Cornell Medical Center and served as an Assistant Professor of Neurosurgery and Associate Research Professor of Surgery at Cornell, where he co-directed the Aitken Laboratory in Neurosurgery.
33. Omid Farokhzad
Co-Founder, Chair, and Chief Executive Officer, Seer
Omid Farokhzad is the Co-Founder, Chair, and Chief Executive Officer for Seera, a life sciences company dedicated to developing transformative products that unlock new insights into the proteome. Seer's Proteograph Product Suite is an integrated solution that combines proprietary engineered nanoparticles, consumables, automation instrumentation, and software, enabling deep, unbiased proteomic analysis at scale within hours.
Previously, Farokhzad was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 175 papers and is an inventor of over 200 issued and pending patents. Farokhzad previously founded BIND Therapeutics, Selecta Biosciences, and Tarveda Therapeutics. Farokhzad holds an MD and master’s degree from Boston University and an MBA from the MIT Sloan School of Management.
34. Rachel Haurwitz
President, CEO and Co-Founder, Caribou Biosciences
Rachel Haurwitz is a Co-Founder of Caribou Biosciences and has been its President and Chief Executive Officer and a director since the company’s inception in 2011. Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease.
Haurwitz is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. She also serves on the board of directors of the Biotechnology Organization. Haurwitz holds a bachelor’s degree in biological sciences from Harvard College and a PhD in molecular and cell biology from the University of California, Berkeley.
35. Yujiro Hata
Co-Founder and CEO, IDEAYA Biosciences
Yujiro Hata currently serves as the Founder and CEO of IDEAYA Biosciences, an oncology-focused precision medicine company, which he founded in 2015. Hata has more than 20 years of experience building companies that have developed innovative therapies. IDEAYA is a precision medicine oncology company with deep research and development expertise in synthetic lethality. The company is focused on the discovery and development of targeted therapeutics for patient populations identified through molecular diagnostics.
Previously, Hata served as an Executive-in-Residence at 5AM Ventures. He was the Chief Operating Officer at Flexus Biosciences, where he played a key role in the company's acquisition by Bristol-Myers Squibb, and later served as Chief Operating Officer at RAPT Therapeutics. Hata also served as Vice President of Corporate Development and Strategy at Onyx Pharmaceuticals.
Hata serves on the Boards of Directors for Xencor and Expansion Therapeutics and is a Board Member of the Moores Cancer Center at the University of California, San Diego. He holds an MBA from the University of Pennsylvania and a bachelor’s degree in chemistry from Colorado College, with additional undergraduate studies in chemistry and biology at Oxford University.
36. Noam Solomon
Co-Founder and CEO, Immunai
Noam Solomon is the Co-Founder and Chief Executive Officer of Immunai, a company aiming to reprogram the immune system for better detection, diagnosis, and treatment of disease, and discovery of novel therapeutics.
Immunai uses single-cell genomics and machine learning to discover and improve development of novel therapeutics by decoding the immune system. The team of 170 employees, 85 of whom are PhDs or MDs, is composed of experts in genomics, machine learning, bioinformatics, immunology, and software engineering.
Prior to co-founding Immunai, Solomon had a dual career in both the industry and academia. Solomon has a double PhD in math and computer science and served as a post-doctoral researcher in the mathematics department at the Massachusetts Institute of Technology, and in the Center of Mathematical Sciences and Applications at Harvard University.
37. Aya Jakobovits
Founder and Board Member, Adicet Bio
Aya Jakobovits is a Board Member at Adicet Bio, Inc., a clinical-stage biotechnology company she founded in 2014, where she served as President and Chief Executive Officer until 2018. Adicet Bio is dedicated to discovering and developing allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer.
Dr. Jakobovits previously served as a Venture Partner at OrbiMed and as the President and Founding CEO of Kite Pharma, Inc. Before joining Kite, she was Executive Vice President and Head of Research and Development at Agensys, Inc., where she led R&D, clinical, and corporate development operations. Earlier in her career, Dr. Jakobovits held positions at Abgenix, Inc., serving as Director of Discovery Research and Principal Scientist.
Dr. Jakobovits holds a bachelor’s degree from The Hebrew University of Jerusalem, along with a master’s degree in chemistry and a PhD in life sciences from the Weizmann Institute of Science in Israel. She was also a postdoctoral fellow at UCSF and Genentech.
38. Carol Suh
Co-Founder and Chief Operating Officer, Neumora Therapeutics
Carol Suh is a Co-Founder of Neumora Therapeutics and has served as the Chief Operating Officer since 2023. She previously held the position of Senior Vice President of Strategy and served as Vice President of Business Development. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed.
Suh has been a member of ARCH Venture Partners since 2018 and became a Partner in 2021. While at ARCH, she has been involved in company creation and helped build multiple companies across the fields of cell and gene therapy, neuroscience, oncology and immunology. Suh also co-founded Orbital Therapeutics and has served on its board of directors since 2022. She also serves on the board of directors of HI-Bio and the Metrodora Foundation.
Prior to ARCH, Suh helped launch Magenta Therapeutics, a biotechnology company, in 2016 and served as Business Development and Corporate Strategy Associate. Before that, she was a consultant at Trinity Partners. Suh began her career in R&D with GlaxoSmithKline’s Regenerative Medicine group. Suh holds a bachelor’s degree in molecular and cellular biology from Harvard University, a master of philosophy from Yale University, and an MBA from Stanford Graduate School of Business.
39. Jeff Smith
Co-Founder and Chief Research Officer, Precision BioSciences
Jeff Smith is the Co-Founder and Chief Research Officer of Precision BioSciences, a gene editing company focused on improving life through its novel and proprietary ARCUS genome editing platform. This platform distinguishes itself from other technologies by its unique cutting mechanism, smaller size, and simpler structure. Smith is recognized as a pioneer in genome editing, having made significant observations that contributed to the development of the first successful engineered editing nucleases.
Smith received his PhD from Johns Hopkins University, where he developed and characterized custom nucleases for genome engineering. He continued his work in protein engineering at Duke University, helping to lay the groundwork for Precision BioSciences' ARCUS genome editing technology. As an inventor, Smith holds over 75 foundational, issued patents related to the production and use of genome editing tools.
40. Miguel Garcia-Guzman
Founder and Board Member, Rakuten Medical
Miguel Garcia-Guzman is the Founder and a Board Member of Rakuten Medical, a global biotechnology company that develops and commercializes precision cell-targeting therapies based on its proprietary Alluminox platform. This platform has demonstrated rapid and selective cell killing and tumor necrosis in preclinical studies. He previously founded Aspyrian Therapeutics, Inc., where he secured an exclusive license for the further development of the National Cancer Institute’s photoimmunotherapy technology.
Previously, Dr. Garcia-Guzman was a Senior Scientist, Associated Director, and Research Fellow at Vertex Pharmaceuticals and before that a Senior Scientist at Arcaris Therapeutics Inc. He earned a PhD in molecular biology, pharmacology, and neuroscience from the University of Alicante Institute of Neurosciences in Spain and an undergraduate degree in chemistry from the University of Alicante.
41. Sean Tucker
Founder, Senior Vice President and Chief Scientific Officer, Vaxart
Dr. Sean Tucker is the Founder and Chief Scientific Officer of Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration to eliminate the risk of needle-stick injury. Vaxart's pill vaccine delivery platform aims to provide a method for administering recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications.
Dr. Tucker has held numerous scientific and engineering roles at various biotechnology companies. He previously served as Vice President of Research and Director of Immunology at Vaxart. Dr. Tucker holds a bachelor’s degree in chemical engineering from the University of Washington, a master’s degree in chemical engineering from the University of California, Berkeley, and a PhD in immunology from the University of Washington.
42. Chris Varma
Co-Founder, Chairman and CEO, Frontier Medicines
Chris Varma is the Co-Founder, Chairman, and Chief Executive Officer of Frontier Medicines, a clinical stage precision medicine company pioneering medicines to transform treatment for genetically-defined patient populations, starting with oncology and immunology. Varma is an experienced entrepreneur and investor in the life sciences industry.
Prior to co-founding Frontier Medicines, Varma co-founded Blueprint Medicines and served as its President and CEO and co-founded Warp Drive Bio. Varma has also served in investor roles at leading venture capital firms, including MPM Capital, Third Rock Ventures, and Flagship Pioneering. Varma began his career at Novartis AG, overseeing efforts spanning business development, strategy, and sales and marketing.
Varma holds a PhD in biomedical sciences from the Harvard-MIT Program in Health Sciences and Technology, a master’s degree in management from Stanford University, and both a bachelor’s and master’s degree in computer science from Stanford University.
43. George Church
Co-Founder, EGenesis
Dr. George Church is the Co-Founder of eGenesis, a company focused on developing genome engineering techniques to create safe and effective transplantable organs, addressing the global organ shortage and improving organ failure treatment. Dr. Church has co-founded more than 14 biotech companies, authored over 400 papers, and holds 60 patents in his name.
Dr. Church is also the Robert Winthrop Professor of Genetics at Harvard Medical School, a Professor of Health Sciences and Technology at Harvard and MIT, and a core faculty member of the Wyss Institute. He is the Principal Investigator of the Center for Genomically Engineered Organs, the Harvard/MIT DOE Genomes-to-Life Center, the Lipper Center for Computational Genetics, and is a founding core member of the Wyss Institute for Biologically Inspired Engineering. Dr. Church holds a PhD in biochemistry and molecular biology from Harvard University.
44. Shao-Lee Lin
Co-Founder, ACELYRIN
Shao-Lee Lin is the Founder of ACELYRIN, a late-stage public biopharma company that identifies, acquires, and accelerates the development and commercialization of transformative medicines for patients with serious diseases. Lin is an experienced director for both public and non-profit boards. Lin emphasizes collaboration and calculated risk-taking to improve the lives of patients with serious diseases. She is motivated by a sense of urgency and innovation in her approach to healthcare.
Previously, Lin was an EVP, Head of Research and Development, and Chief Scientific Officer at Horizon and before that a Corporate Officer and VP of Therapeutic Areas, Development Excellence, and International Development at AbbVie. Earlier in her career she worked with Amgen, Inc. as an executive medical director of global development. Lin earned an MD and PhD in immunology from The Johns Hopkins University School of Medicine and an undergraduate degree in chemical engineering and biochemistry from Rice University.
45. Mir Imran
Founder, Rani Therapeutics
Mir Imran is the Founder of Rani Therapeutics, a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Imran is a prolific healthcare innovator and entrepreneur who has been developing and commercializing medical innovations for more than 40 years.
Imran’s innovations have been developed at his life science R&D lab and incubator, InCube Labs. As an entrepreneur, Imran has founded more than 20 life sciences companies, with 15 of them having seen liquidity events through IPOs or acquisitions. Additionally, Imran is known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. He holds a master's degree in bioengineering and a bachelor’s degree in electrical engineering from Rutgers University and also attended CMDNJ/Rutgers Medical School.
46. Kristen Fortney
Co-Founder and CEO, BioAge Labs
Kristen Fortney is the Co-Founder, Chief Executive Officer, and board member of BioAge Labs, a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials.
Fortney is a scientifically trained biotech executive with extensive experience building discovery platforms, building teams, fundraising, and scientific and clinical strategy. She serves as an advisor to multiple biotechnology companies. Fortney’s scientific background is in aging biology, genetics, and bioinformatics. She holds a PhD in medical biophysics from the University of Toronto, and did postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation/American Federation for Aging Research.
47. Jennifer Petter
Founder and Chief Scientific Officer, Arrakis Therapeutics
Jennifer Petter is a Founder and Chief Scientific Officer of Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. An experienced drug hunter and life sciences executive, Dr. Petter has conducted research across various fields, currently concentrating on RNA at Arrakis. She has authored or co-authored over 50 papers and holds more than 50 patents and patent applications.
Prior to founding Arrakis, Dr. Petter served as Vice President of Chemistry at Celgene and held positions at Mersana Therapeutics, Biogen, and the Sandoz Research Institute. She is an active member of several professional organizations, including the American Association of Cancer Research, the Society of Neuro-Oncology, and the RNA Society, and serves as an associate member of the American Society of Clinical Oncology.
Dr. Petter is also involved with the scientific advisory boards of Cygnal Therapeutics and PIC Therapeutics, as well as the boards of directors for OUTBio and Theon Therapeutics. She holds a bachelor’s degree from Dartmouth College, a PhD from Duke University, and completed postdoctoral research at Columbia University.
48. Peter Diamandis
Co-Founder and Vice Chairman, Human Longevity
Peter Diamandis is the Co-Founder and Vice Chairman of Human Longevity Inc. (HLI), a genomics-based, health intelligence company creating the world’s largest and most comprehensive database of whole genome, phenotype and clinical data. By leveraging large-scale computing and machine learning, Human Longevity aims to uncover novel insights for personalized health applications.
As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital, and education. He is Co-Founder of BOLD Capital Partners, a venture fund with $500 million investing in exponential technologies, and Co-Founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis graduated from Harvard University with an MD, and from Massachusetts Institute of Technology with a master’s degree in aeroastro and an undergraduate degree in molecular biology.
49. Taylor Schreiber
Co-Founder and Chief Executive Officer, Shattuck Labs
Taylor Schreiber is the Co-Founder, Chief Executive Officer, and board member at Shattuck Labs, a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases and cancer. Shattuck is developing a potentially first-in-class antibody for the treatment of IBD and other inflammatory autoimmune diseases. Schreiber is the lead inventor of Shattuck’s ARC technology platform.
Before Schreiber’s appointment as CEO, he served as the company’s Chief Scientific Officer. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc. Schreiber was also the co-inventor of Pelican Therapeutics’ TNFRSF25 agonist technology where he served as Chairman of the Scientific Advisory Board. Schreiber received both his MD and PhD degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine and received his bachelor’s degree in biology from Bucknell University.
50. Frederique Menzaghi
Co-Founder, Chief Scientific Officer, Senior VP Research and Clinical Development, Cara Therapeutics
Frederique Menzaghi is the Co-Founder, Chief Scientific Officer, and Senior VP of Research and Clinical Development of Cara Therapeutics, a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. Menzaghi has 30 years of proven track record in building and leading interdisciplinary teams spanning the entire drug development process from exploratory drug discovery to product approval in biotechnology setting, with recent worldwide approval of intravenous Korsuva (Difelikefalin), a breakthrough therapy for hemodialysis patients suffering from chronic pruritus.
Previously, Menzaghi was a VP of Pharmacology and Business Development at PsychoGenics and before that a Research Director of Pharmacology at Arena Pharmaceuticals, acquired by Pfizer. Earlier in her career, Menzaghi worked as a research scientist at SIBIA Neurosciences, which was later acquired and integrated into Merck Research Laboratories. Menzaghi earned a PhD in neurosciences from the University Louis Pasteur in Strasbourg, France and a master’s degree in clinical psychology and neurophysiology.
